Share Email Print

Journal of Biomedical Optics

Routine experimental system for defining conditions used in photodynamic therapy and fluorescence photodetection of (non-) neoplastic epithelia
Author(s): Norbert Lange; Laurent Vaucher; Alexandre Marti; Anne-Lise Etter; Patrick Gerber; Hubert van den Bergh; Patrice Jichlinski; Pavel Kucera
Format Member Price Non-Member Price
PDF $20.00 $25.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

A common method to induce enhanced short-term endogenous porphyrin synthesis and accumulation in cell is the topical, systemic application of 5-aminolevulinic acid or one of its derivatives. This circumvents the intravenous administration of photosensitizers normally used for photodynamic therapy (PDT) of fluorescence photodetection. However, in the majority of potential medical indications, optimal conditions with respect to the porphyrin precursor or its pharmaceutical formulation have not yet been found. Due to ethical restrictions and animal right directives, the number of available test objects is limited. Hence, definition and use of nonanimal test methods are needed. Tissue and organ cultures are a promising approach in replacing cost intensive animal models in early stages of drug development. In this paper, we present a tissue culture, which can among others be used routinely to answer specific questions emerging in the field of photodynamic therapy and fluorescence photodetection. This technique uses mucosae excised from sheep paranasal sinuses or pig bladder, which is cultured under controlled conditions. It allows quasiquantitative testing of different protoporphyrin IX precursors with respect to dose-response curves and pharmacokinetics, as well as the evaluation of different incubation conditions and/or different drug formulations. Furthermore, this approach, when combined with the use of electron microscopy and fluorescence-based methods, can be used to quantitatively determine the therapeutic outcome following protoporphyrin IX-mediated PDT.

Paper Details

Date Published: 1 April 2001
PDF: 9 pages
J. Biomed. Opt. 6(2) doi: 10.1117/1.1352751
Published in: Journal of Biomedical Optics Volume 6, Issue 2
Show Author Affiliations
Norbert Lange, Swiss Federal Institute of Technology (Switzerland)
Laurent Vaucher, Univ. of Lausanne (Switzerland)
Alexandre Marti, Centre Hopitalier Univ. Vaudois (Switzerland)
Anne-Lise Etter, Univ. of Lausanne (Switzerland)
Patrick Gerber, Univ. of Lausanne (Switzerland)
Hubert van den Bergh, Swiss Federal Institute of Technology (Switzerland)
Patrice Jichlinski, Centre Hopitalier Univ. Vaudois (Switzerland)
Pavel Kucera, Univ. Lausanne (Switzerland)

© SPIE. Terms of Use
Back to Top